European Patent Office Report Compares Compulsory Licensing Practices By Country 01/03/2019 by Intellectual Property Watch Leave a Comment The European Patent Office has published a report detailing differences in the laws and procedures of European countries for the granting of compulsory licences.
Rise Of The Machines: Experts Look At AI, Robotics And The Law 27/02/2019 by William New, Intellectual Property Watch 2 Comments NEW YORK — Artificial intelligence, robots, and the law, are all changing a rapid pace. A panel of experts at a recent event at Fordham Law School discussed latest developments and signs of the limits of the law when applied to AI areas like facial recognition, automated weapons systems, and financial technology.
Patents Under Debate As Pharma Executives Face US Senate Committee 27/02/2019 by William New, Intellectual Property Watch Leave a Comment Executives of seven large pharmaceutical companies faced questioning yesterday from the United States Senate Finance Committee over high drug prices in the US, especially compared with other developed countries. One issue that came under the microscope was patents.
Asian NGOs Raise Concern Over IP And Seeds In RCEP Trade Deal 26/02/2019 by William New, Intellectual Property Watch 1 Comment The Regional Comprehensive Economic Partnership (RCEP) trade agreement under negotiation among Asia and Pacific nations must not include measures that would undercut countries’ ability to protect diverse local farming systems and sustainable plant genetic resources for food and agriculture, a range of Asian nongovernmental organisations argue. Groups in India, Malaysia and the Philippines this week specifically called for the RCEP not to include the high-level protections under the International Union for the Protection of New Varieties of Plants (UPOV).
New Research Study Describes DNDi As A “Commons” For Public Health 25/02/2019 by David Branigan, Intellectual Property Watch Leave a Comment Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.”
In Memoriam: Dilip Shah (1941-2019) 25/02/2019 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment Dilip Shah was passionately committed to the twin causes of promoting fair access to medicines around the world, and to the success of the local Indian pharmaceutical industry. A bright light is out, writes Prof. Frederick Abbott.
D G Shah, Founder Of Indian Pharmaceutical Alliance, Dies At Age 77: Economic Times 22/02/2019 by William New, Intellectual Property Watch 1 Comment Dilip Shah, founder of the Indian Pharmaceutical Alliance (IPA) the organisation that represented the interests of Indian drug makers passed away in Mumbai on Friday. He was 77. Known in the industry as “DG”, Mr Shah started the IPA when the Indian pharma companies were trying to find their feet in the global pharma landscape that was dominated by the multinational pharma companies predominantly based out of Europe and USA. Shah who himself spent most of his career with the MNC drug companies …
Faced With Unreasonable Medicines Prices, The Netherlands Introduces Pharmacy Exemption In Patent Law 22/02/2019 by Intellectual Property Watch Leave a Comment Ellen ‘t Hoen writes: On 1 February 2019, article 53(3), second sentence of the Dutch Patent Act 1995 came into force introducing a patent exemption for the preparation of medicines in a pharmacy.
EU Members Adopt Plan To Make Europe A Leader In Artificial Intelligence 19/02/2019 by William New, Intellectual Property Watch 1 Comment The European Council of member states has adopted an all-encompassing plan to make Europe a global leader in artificial intelligence and integrate AI into all aspects of regional life. The plan, which comes as Europe has been identified as lagging in AI research and investment behind the United States and China, includes strong calls to ramp up investment while carefully considering AI’s impact on labour and ethics.
WTO IP Council: Praise For Public-Private Partnerships, Use Of Competition Law To Fight High Drug Prices 18/02/2019 by Catherine Saez, Intellectual Property Watch Leave a Comment At the World Trade Organization Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) – which met on 13 February and finished in one day – discussions on IP and innovation, and IP and the public interest delineated points of views but also provided concrete examples of successful use of public-private partnerships, and use of competition law to prevent excessive pricing.
